Patents by Inventor Jun Ohsumi
Jun Ohsumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7981421Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: January 13, 2010Date of Patent: July 19, 2011Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
-
Patent number: 7939081Abstract: The present invention provides a process for producing cercosporamide comprising culturing a fungus belonging to the genus Lachnum and/or fungus belonging to the genus Pseudaegerita and recovering cercosporamide from the culture thereof. In addition, the present invention provides cercosporamide acquired according to this production process. Further, the present invention provides novel microorganisms consisting of Lachnum fuscescens SANK 19096, Lachnum calycioides SANK 12497, Lachnum caesaliatum SANK 10906, and Pseudaegerita websteri SANK 11006.Type: GrantFiled: August 8, 2006Date of Patent: May 10, 2011Assignee: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Hosoya, Jun Ohsumi, Kiyoshi Hamano, Yasunori Ono, Masami Miura
-
Publication number: 20110002887Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: ApplicationFiled: January 13, 2010Publication date: January 6, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventors: Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Tong Zhou, Donald J. Buchsbaum, Kimihisa Ichikawa, Jun Ohsumi
-
Publication number: 20100152467Abstract: The present invention provides a process for producing cercosporamide comprising culturing a fungus belonging to the genus Lachnum and/or fungus belonging to the genus Pseudaegerita and recovering cercosporamide from the culture thereof. In addition, the present invention provides cercosporamide acquired according to this production process. Further, the present invention provides novel microorganisms consisting of Lachnum fuscescens SANK 19096, Lachnum calycioides SANK 12497, Lachnum caesaliatum SANK 10906, and Pseudaegerita websteri SANK 11006.Type: ApplicationFiled: August 8, 2006Publication date: June 17, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi Hosoya, Jun Ohsumi, Kiyoshi Hamano, Yasunori Ono, Masami Miura
-
Patent number: 7718377Abstract: The present invention provides a screening method for a compound which is highly safe and has a prophylactic or therapeutic effect on diabetes, and a highly safe pharmaceutical composition for the prophylaxis or treatment of diabetes. Specifically, a drug for the prophylaxis or treatment of diabetes, which contains, as an active ingredient, a compound having PPAR? activation activity and PTP inhibitory activity, and a method of screening for the drug are provided.Type: GrantFiled: May 28, 2004Date of Patent: May 18, 2010Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Kazushi Araki, Jun Ohsumi, Makoto Yachi
-
Patent number: 7704502Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: May 22, 2007Date of Patent: April 27, 2010Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
-
Publication number: 20090137499Abstract: The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I): wherein R1 represents a hydrogen atom, an amino group, a hydroxy C1-C6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, etc.; R4 represents a hydrogen atom, a C2-C7 acyl group, etc.; R5, R6, R7, and R8 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, provided that R5, R6, R7 and R8 are not hydrogen atoms at the same time; n is 0 to 4; and X is CH or N.Type: ApplicationFiled: August 3, 2007Publication date: May 28, 2009Inventors: Takeshi Honda, Minoru Oguchi, Masao Yoshida, Ryo Okuyama, Tsuneaki Ogata, Manabu Abe, Kenjiro Ueda, Jun Ohsumi, Masanori Izumi
-
Publication number: 20090088462Abstract: Method for treatment of a human patient having hypoadiponectinemia. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically salt thereof is administered in an amount effective to raise the level of adiponectine in said patient.Type: ApplicationFiled: December 14, 2006Publication date: April 2, 2009Applicant: Daiichi Sankyo Company, LimitedInventors: Shoichi Kanda, Jun Ohsumi
-
Publication number: 20090036492Abstract: The present invention relates to a novel cercosporamide derivative, a pharmacologically acceptable salt thereof or an ester thereof which has an excellent hypoglycemic effect and is useful as a therapeutic and/or prophylactic agent for diabetes.Type: ApplicationFiled: August 8, 2006Publication date: February 5, 2009Inventors: Akihiro Furukawa, Jun Ohsumi, Tsuyoshi Arita, Takehiro Fukuzaki, Kazushi Araki, Makoto Mori, Takayuki Momose, Takeshi Honda, Masanori Kuroha, Ryo Okuyama, Susumu Satoh
-
Patent number: 7279160Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: October 25, 2002Date of Patent: October 9, 2007Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. Lobuglio, Donald J. Buchsbaum
-
Publication number: 20070059762Abstract: The present invention provides a screening method for a compound which is highly safe and has a prophylactic or therapeutic effect on diabetes, and a highly safe pharmaceutical composition for the prophylaxis or treatment of diabetes. Specifically, a drug for the prophylaxis or treatment of diabetes, which contains, as an active ingredient, a compound having PPAR? activation activity and PTP inhibitory activity, and a method of screening for the drug are provided.Type: ApplicationFiled: May 28, 2004Publication date: March 15, 2007Inventors: Kazushi Araki, Jun Ohsumi, Makoto Yachi
-
Publication number: 20070049515Abstract: A method for treating a disease, in which side effects (for example, edema) are suppressed while maintaining appropriate pharmaceutical effects. The method involves a cycle of administration of the insulin sensitizer wherein the dosage thereof is reduced or withdrawn alternated with administration of an effective dose.Type: ApplicationFiled: September 22, 2006Publication date: March 1, 2007Applicant: SANKYO COMPANY, LIMITEDInventors: Shoichi Kanda, Kazushi Araki, Jun Ohsumi
-
Patent number: 6972323Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.Type: GrantFiled: February 9, 2000Date of Patent: December 6, 2005Assignee: Sankyo Company, LimitedInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Jun Ohsumi, Masahiko Ohtsuki, Hideyuki Haruyama, Tohru Takahashi, Hiroko Yoshida, Akio Shiraishi, Shin Yonehara
-
Publication number: 20030170817Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.Type: ApplicationFiled: February 5, 2003Publication date: September 11, 2003Applicant: SANKYO COMPANY, LIMITEDInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Jun Ohsumi, Masahiko Ohtsuki, Hideyuki Haruyama, Tohru Takahashi, Hiroko Yoshida, Akio Shiraishi, Shin Yonehara, Kaori Nakahara, Ikuko Tamaki
-
Publication number: 20030133932Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: ApplicationFiled: October 25, 2002Publication date: July 17, 2003Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
-
Publication number: 20030103976Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.Type: ApplicationFiled: August 9, 2002Publication date: June 5, 2003Applicant: Sankyo Company, LimitedInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Jun Ohsumi, Masahiko Ohtsuki, Hideyuki Haruyama, Tohru Takahashi, Hiroko Yoshida, Akio Shiraishi, Shin Yonehara, Kaori Nakahara, Ikuko Tamaki
-
Patent number: 5212068Abstract: Human pancreatic elastase can now be obtained from a genetically engineered source.Type: GrantFiled: October 22, 1990Date of Patent: May 18, 1993Assignee: Sankyo Company LimitedInventors: Yo Takiguchi, Tokio Tani, Ichiro Kawashima, Jun Ohsumi, Hidehiko Furukawa, Toshinori Ohmine
-
Patent number: 5055479Abstract: Compounds of formula (I): ##STR1## and pharmaceutically acceptable salts thereof are valuable in the treatment of cachexia.Type: GrantFiled: June 14, 1989Date of Patent: October 8, 1991Assignee: Sankyo Company, LimitedInventors: Yo Takiguchi, Jun Ohsumi, Yasuo Shimoji, Kazuhiko Sasagawa
-
Patent number: 4985361Abstract: Human pancreatic elastase can now be obtained from a genetically engineered source.Type: GrantFiled: October 13, 1987Date of Patent: January 15, 1991Assignee: Sankyo Company, LimitedInventors: Yo Takiguchi, Tokio Tani, Ichiro Kawashima, Jun Ohsumi, Hidehiko Furukawa, Toshinori Ohmine